Kevin Koch
Chief Executive Officer at EDGEWISE THERAPEUTICS, INC.
Net worth: 6 M $ as of 2024-06-29
Kevin Koch active positions
| Companies | Position | Start | End |
|---|---|---|---|
| EDGEWISE THERAPEUTICS, INC. | Director/Board Member | 2016-12-31 | - |
| Chief Executive Officer | 2016-12-31 | - | |
| President | 2016-12-31 | - | |
| Director of Finance/CFO | 2016-12-31 | 2020-10-15 | |
| Investor Relations Contact | 2016-12-31 | - | |
| Public Communications Contact | 2016-12-31 | - | |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Private Equity Investor | 2016-04-30 | - |
Encycle Therapeutics, Inc.
 Encycle Therapeutics, Inc. BiotechnologyHealth Technology Encycle Therapeutics, Inc. provides biotechnology services. It offers rapid synthesis of drug-like macrocycles or membrane-permeable nacellins which have enormous potential to target intracellular protein-protein interactions. The company was founded by Andrei Yudin is headquartered in Toronto, Canada. | Director/Board Member | - | - |
Neurogastrx, Inc.
 Neurogastrx, Inc. BiotechnologyHealth Technology Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA. | Director/Board Member | 2018-01-03 | - |
Skyhawk Therapeutics, Inc.
 Skyhawk Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Skyhawk Therapeutics, Inc. discovers and develops small molecule therapeutics for RNA-based disease. It is developing drug candidates for cancer, neurological disease, and rare disease. The company was founded by William M. Hanley III and Kathleen McCarthy and is headquartered in Waltham, MA. | Director/Board Member | - | - |
Terremoto Biosciences, Inc.
 Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | Director/Board Member | - | - |
Career history of Kevin Koch
Former positions of Kevin Koch
| Companies | Position | Start | End |
|---|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Director/Board Member | 2017-02-12 | 2020-10-27 |
| Independent Dir/Board Member | 2017-02-12 | 2020-10-27 | |
| BIOGEN INC. | President | 2013-11-30 | 2015-08-31 |
| ARRAY TECHNOLOGIES, INC. | Director/Board Member | 2010-09-30 | 2012-10-23 |
| Chief Tech/Sci/R&D Officer | 1998-04-30 | 2013-11-28 | |
| Founder | 1997-12-31 | 2013-11-28 | |
| President | 1998-04-30 | 2013-11-28 | |
| ░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Training of Kevin Koch
| Stony Brook University | Undergraduate Degree |
| Rochester Christian University | Doctorate Degree |
Statistics
International
| United States | 15 |
| Canada | 2 |
Operational
| Director/Board Member | 9 |
| President | 3 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 12 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 5 |
|---|---|
| AMGEN INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| EDGEWISE THERAPEUTICS, INC. | Health Technology |
| Private companies | 8 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Inflammation Research Association, Inc.
 Inflammation Research Association, Inc. Miscellaneous Commercial ServicesCommercial Services Inflammation Research Association, Inc. engages in encouraging scientists, researchers, students, teachers and clinicians with an interest in inflammation biology. The company is headquartered in Newcastle, WA. | Commercial Services |
Ataxion, Inc.
 Ataxion, Inc. BiotechnologyHealth Technology Ataxion, Inc. develops novel therapies for rare, debilitating, and underserved neurologic diseases. It focuses on orphan genetic disorders termed hereditary ataxias. It was founded by Josh Resnick and David Grayzel in April 2013 and is headquartered in Cambridge, MA. | Health Technology |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Finance |
Encycle Therapeutics, Inc.
Encycle Therapeutics, Inc. BiotechnologyHealth Technology Encycle Therapeutics, Inc. provides biotechnology services. It offers rapid synthesis of drug-like macrocycles or membrane-permeable nacellins which have enormous potential to target intracellular protein-protein interactions. The company was founded by Andrei Yudin is headquartered in Toronto, Canada. | Health Technology |
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA. | Health Technology |
Skyhawk Therapeutics, Inc.
Skyhawk Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Skyhawk Therapeutics, Inc. discovers and develops small molecule therapeutics for RNA-based disease. It is developing drug candidates for cancer, neurological disease, and rare disease. The company was founded by William M. Hanley III and Kathleen McCarthy and is headquartered in Waltham, MA. | Health Technology |
Terremoto Biosciences, Inc.
Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Kevin Koch
- Experience
